Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Highlights•The recent paradigm shift in drug development due to ketamine is described.•A
historical overview of novel and repurposed antidepressant drugs is provided.•Mechanisms …

While the molecular target of (R, S)-ketamine (ketamine) is thought to be the NMDA receptor,
subanesthetic doses of ketamine have been known to modulate monoaminergic …

For the past decade, ketamine, an N-methyl-D-aspartate receptor (NMDAr) antagonist, has
been considered a promising treatment for major depressive disorder (MDD). Unlike the …

Ketamine induces safe and effective anesthesia and displays unusual cataleptic properties
that gave rise to the term dissociative anesthesia. Since 1970, clinicians only utilized the …

Rationale Ketamine has rapid antidepressant effects that represent a significant advance in
treating depression, but its poor safety and tolerability limit its clinical utility. Accreting …

Major depressive disorder is typically treated with selective serotonin reuptake inhibitors
(SSRIs), however, SSRIs take approximately six weeks to produce therapeutic effects, if any …

The major depressive disorder (MDD) working group of the Psychiatric Genomics
Consortium (PGC) has published a genome-wide association study (GWAS) for MDD in …